Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital.

Glob Reg Health Technol Assess

Cergas (Centro di Ricerche sulla Gestione dell'Assistenza Sanitaria e Sociale), SDA Bocconi School of Management, Università Bocconi, Milano - Italy.

Published: March 2021

AI Article Synopsis

  • Dose banding is a new method for preparing intravenous chemotherapy by creating fixed dosage bags weekly, replacing traditional daily individually-prepared bags.
  • The study compared costs of three methods: daily individualized bags, weekly non-individualized bags (dose banding), and commercial ready-to-use bags, evaluating five cancer drugs.
  • Results indicated potential cost savings from dose banding, with estimated savings ranging from €10,998 for trastuzumab to €169,429.60 for paclitaxel, along with benefits like better work conditions and reduced waste.

Article Abstract

Introduction: Dose banding is an original approach that manages intravenous (IV) chemotherapy preparation by generating on a weekly basis a series of bags containing scaled dosages of the active agent. These predetermined, fixed dosage bags are intended to replace the traditional bags prepared daily that contain fully individualized dosages.

Methods: Three different scenarios were examined: (1) the current method of daily preparation of individualized bags at the hospital pharmacy; (2) the weekly preparation at the hospital pharmacy of non-individualized bags containing discrete, predefined doses covering an adequate range of doses (dose banding); (3) the use of commercial ready-to-use bags based on the same approach of dose banding. The objective of this study was to compare these three different approaches in terms of cost per patient. We considered five cancer drugs (gemcitabine, oxaliplatin, paclitaxel, trastuzumab and 5-fluorouracil) that were suitable for the dose ranging approach. Appropriate dose bands for these five agents were identified. Costs were estimated for each of the three approaches.

Results: A total of 13,490 fully individualized bags were studied, which corresponded to the real bags prepared at our institution for these five agents in 2018. Dose banding was predicted to determine savings ranging from €10,998 (-0.84%) for trastuzumab to €169,429.60 (-8.39%) for paclitaxel.

Conclusion: The introduction of dose banding can determine economic savings along with other advantages, such as improved work conditions, management reorganization and containment of waste. The pharmaceutical industry can hopefully support these experiences by producing ready-to-use bags in predetermined dosages.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616189PMC
http://dx.doi.org/10.33393/grhta.2021.2202DOI Listing

Publication Analysis

Top Keywords

dose banding
24
bags
10
intravenous chemotherapy
8
dose
8
introduction dose
8
bags prepared
8
fully individualized
8
individualized bags
8
hospital pharmacy
8
ready-to-use bags
8

Similar Publications

Ethambutol is used to treat tuberculosis (TB) in individuals living with HIV. Low concentrations of ethambutol have been reported in patients dosed with the World Health Organization (WHO)-recommended first-line regimen. We analyzed the pharmacokinetics of ethambutol in 61 HIV-positive individuals diagnosed with drug-sensitive TB enrolled in the tuberculosis and highly active antiretroviral therapy (TB-HAART) study.

View Article and Find Full Text PDF

Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome.

Adv Ther

December 2024

Acadia Pharmaceuticals Inc., 12830 El Camino Real, Suite 400, San Diego, CA, 92130, USA.

Introduction: Weight-banded trofinetide dosing improved physician- and caregiver-rated efficacy measures and had acceptable tolerability in patients aged 2‒4 years (DAFFODIL study) and 5‒20 years (LAVENDER study) with Rett syndrome (RTT). Selection of weight-banded dosing regimens for these studies was based on population pharmacokinetic (popPK) modeling and exposure simulations. This study applied an updated popPK model to confirm steady-state trofinetide exposures achieved in DAFFODIL patients were within target range.

View Article and Find Full Text PDF

Introduction: Oral trofinetide administered using a body weight-banded dosing regimen was approved in the US for the treatment of Rett syndrome (RTT) in patients aged ≥ 2 years. This approval was principally based on efficacy and safety findings of the phase 3 LAVENDER study in girls and women aged 5-20 years with RTT and extended to younger children aged 2-4 years with supporting data from the DAFFODIL study. Weight-banded dosing regimens were selected based on early clinical population pharmacokinetic (popPK) modeling and different scenario simulations.

View Article and Find Full Text PDF

Gamma irradiation was applied to the tachyzoites Toxoplasma gondii virulent strain at doses of 0.25, 0.5, 1, 1.

View Article and Find Full Text PDF

This study investigates the OSL properties of four natural fluorite color varieties (green, purple, blue-yellow banded and yellow) under green light stimulation. Thermoluminescence reveals two peaks, with the green sample showing the strongest glow. OSL exhibits a fast initial decay followed by a slower one, with phototransfer observed in purple and yellow.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!